ACUTE MYELOID LEUKEMIA WITH KMT2A REARRANGEMENT
Clinical trials for ACUTE MYELOID LEUKEMIA WITH KMT2A REARRANGEMENT explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIA WITH KMT2A REARRANGEMENT trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA WITH KMT2A REARRANGEMENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to improve leukemia treatment
Disease control Recruiting nowThis early-phase trial tests the safety and best dose of a new targeted drug (SNDX-5613) when added to standard chemotherapy for adults with a specific type of acute myeloid leukemia (AML) that has changes in the NPM1 or MLL genes. The study enrolls 28 newly diagnosed patients ag…
Matched conditions: ACUTE MYELOID LEUKEMIA WITH KMT2A REARRANGEMENT
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New drug combo targets Hard-to-Treat leukemia in early trial
Disease control Recruiting nowThis early-phase study tests whether combining two targeted drugs, SNDX-5613 and gilteritinib, is safe and effective for adults with a specific type of acute myeloid leukemia (AML) that has returned or not responded to treatment. The cancer must have a FLT3 mutation plus either a…
Matched conditions: ACUTE MYELOID LEUKEMIA WITH KMT2A REARRANGEMENT
Phase: PHASE1 • Sponsor: Uma Borate • Aim: Disease control
Last updated May 13, 2026 16:03 UTC